Urologic Oncology: Seminars and Original Investigations
Volume 24, Issue 5 , Pages 396-402 , September 2006

Reduced incidence of bony metastasis at initial prostate cancer diagnosis: Data from CaPSURE™

  • Charles J. Ryan, M.D.

      Affiliations

    • Department of Medicine, and UCSF Comprehensive Cancer Center, University of California–San Francisco, San Francisco, CA 94143, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-415-353-9279; fax: +1-415-353-7779.
    • ,
  • Eric P. Elkin, M.P.H.

      Affiliations

    • Department of Urology, and UCSF Comprehensive Cancer Center, University of California–San Francisco, San Francisco, CA 94143, USA
    • ,
  • Eric J. Small, M.D.

      Affiliations

    • Department of Medicine, and UCSF Comprehensive Cancer Center, University of California–San Francisco, San Francisco, CA 94143, USA
    • ,
  • Janeen Duchane, Ph.D.

      Affiliations

    • TAP Pharmaceutical Products, Inc., Lake Forest, IL 60045, USA
    • ,
  • Peter Carroll, M.D.

      Affiliations

    • Department of Urology, and UCSF Comprehensive Cancer Center, University of California–San Francisco, San Francisco, CA 94143, USA

Received 12 July 2005 ,Revised 1 September 2005 ,Accepted 2 September 2005.

References 

  1. Farkas A , Schneider D , Perrotti M , et al.   National trends in the epidemiology of prostate cancer, 1973 to 1994: Evidence for the effectiveness of prostate-specific antigen screening . Urology . 1998;52:444–448
  2. Smith DS , Catalona WJ , Herschman JD . Longitudinal screening for prostate cancer with prostate-specific antigen . JAMA . 1996;276:1309–1315
  3. Tannock IF , de Wit R , Berry WR , et al.   Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer . N Engl J Med . 2004;351:1502–1512
  4. Petrylak DP , Tangen CM , Hussain MH , et al.   Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer . N Engl J Med . 2004;351:1513–1520
  5. Eisen SA , Waterman B , Skinner CS , et al.   Sociodemographic and health status characteristics with prostate cancer screening in a national cohort of middle-aged male veterans . Urology . 1999;53:516–522
  6. Thompson IM , Pauler DK , Goodman PJ , et al.   Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter . N Engl J Med . 2004;350:2239–2246
  7. Lubeck DP , Litwin MS , Henning JM , et al.  CaPSURE Research Panel   The CaPSURE database: A methodology for clinical practice and research in prostate cancer (Cancer of the Prostate Strategic Urologic Research Endeavor) . Urology . 1996;48:773–777
  8. Cooperberg MR , Broering JM , Latini DM , et al.   Patterns of practice in the United States: Insights from CaPSURE on prostate cancer management . Curr Urol Rep . 2004;5:166–172
  9. American Joint Committee on Cancer American Cancer Society . In:  Greene FL editors. AJCC cancer staging manual . 6th ed.. New York (NY): Springer; 2002;
  10. Kuczmarski RJ , Flegal KM . Criteria for definition of overweight in transition: Background and recommendations for the United States . Am J Clin Nutr . 2000;72:1074–1081
  11. Kane CJ , Bassett WW , Sadetsky N , et al.   Obesity and prostate cancer clinical risk factors at presentation: data from CaPSURE . J Urol . 2005;173:732–736
  12. Cooperberg MR , Lubeck DP , Mehta SS , et al.   Time trends in clinical risk stratification for prostate cancer: Implications for outcomes (data from CaPSURE) . J Urol . 2003;170:S21–S25

☆ CaPSURE™ is supported by TAP Pharmaceutical Products, Inc. (Lake Forest, IL). This research was additionally funded by the National Institutes of Health/National Cancer Institute University of California–San Francisco, SPORE—Special Program of Research Excellence p50c89520.

PII: S1078-1439(05)00226-7

doi: 10.1016/j.urolonc.2005.09.003

Urologic Oncology: Seminars and Original Investigations
Volume 24, Issue 5 , Pages 396-402 , September 2006

Article Tools

* Image Usage & Resolution